Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.thyrocare.com | |
Market Cap | 2,219.89 Cr. | |
Enterprise Value(EV) | 2,201.42 Cr. | 2022-12 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 13.81 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 30.36 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 45.91 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 97.06 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 4.32 | Calculated using Price: 419.45 |
Dividend Yield | 3.58 | Period Ending 2022-03 |
No. of Shares Subscribed | 5.29 Cr. | 52,930,043 Shares |
FaceValue | 10 | |
Company Profile | ||
Thyrocare Technologies is an India-based healthcare service provider. The Company operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The Company offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The Company offers cancer diagnosis and water testing through its brands Nueclear and Whaters, respectively. |
1 Day |
|
-1.19% |
1 Week |
|
-7.82% |
1 Month |
|
-7.12% |
3 Month |
|
-31.95% |
6 Month |
|
-38.84% |
1 Year |
|
-45.87% |
2 Year |
|
-51.64% |
5 Year |
|
-30.23% |
10 Year |
|
8 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 15.98 | 16.22 | 11.20 | 22.16 | 19.41 | 22.13 | 28.75 | 37.18 | |
Return on Capital Employed (%) | 24.57 | 25.66 | 21.05 | 33.93 | 31.36 | 35.14 | 38.51 | 48.24 | |
Return on Assets (%) | 13.41 | 14.09 | 10.20 | 20.59 | 17.93 | 18.73 | 22.43 | 30.87 |
Particulars | 9 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12* Rs. Cr. |
Shh. Funds | 276 | 366 | 408 | 443 | 435 | 367 | 427 | 527 | 514 | |
Non Curr. Liab. | 9 | 10 | 9 | 10 | 14 | 21 | 18 | 10 | 6 | |
Curr. Liab. | 7 | 31 | 18 | 20 | 21 | 82 | 95 | 65 | 71 | |
Minority Int. | 36 | 1 | ||||||||
Equity & Liab. | 328 | 407 | 434 | 474 | 470 | 469 | 540 | 601 | 591 | |
Non Curr. Assets | 218 | 273 | 285 | 332 | 334 | 317 | 300 | 331 | 345 | |
Curr. Assets | 111 | 134 | 150 | 142 | 136 | 152 | 240 | 270 | 246 | |
Misc. Exp. not W/O | ||||||||||
Total Assets | 328 | 407 | 434 | 474 | 470 | 469 | 540 | 601 | 591 |
Particulars | 9 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 183 | 241 | 304 | 356 | 403 | 434 | 495 | 589 | 521 | |
Other Income | 8 | 7 | 12 | 23 | 10 | 7 | 12 | 29 | 7 | |
Total Income | 191 | 248 | 317 | 380 | 413 | 441 | 507 | 618 | 528 | |
Total Expenditure | -110 | -147 | -189 | -212 | -249 | -261 | -323 | -354 | -388 | |
PBIDT | 81 | 101 | 128 | 168 | 164 | 180 | 184 | 264 | 140 | |
Interest | 0 | -1 | 0 | 0 | -1 | -2 | -1 | -2 | -2 | |
Depreciation | -13 | -18 | -18 | -20 | -26 | -32 | -30 | -34 | -38 | |
Taxation | -24 | -30 | -39 | -52 | -53 | -52 | -39 | -52 | -28 | |
Exceptional Items | -27 | -2 | -7 | |||||||
PAT | 44 | 52 | 43 | 93 | 85 | 88 | 113 | 176 | 72 | |
Minority Interest | 1 | 0 | ||||||||
Share Associate | 1 | 1 | 1 | |||||||
Other Related Items | 0 | -1 | 0 | |||||||
Consolidated Net Profit | 45 | 52 | 43 | 93 | 85 | 89 | 112 | 176 | 73 | |
Adjusted EPS | 9 | 10 | 8 | 17 | 16 | 17 | 21 | 33 | 14 |
Particulars | 8 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 34 | 68 | 90 | 107 | 100 | 168 | 115 | 113 | |
Cash Fr. Inv. | -18 | -18 | -42 | -43 | -12 | 1 | -49 | -24 | |
Cash Fr. Finan. | -23 | -45 | -49 | -64 | -94 | -165 | -62 | -89 | |
Net Change | -6 | 5 | 0 | 0 | -5 | 4 | 4 | 0 | |
Cash & Cash Eqvt | 5 | 10 | 10 | 10 | 5 | 9 | 13 | 14 |
Mon, 13 Mar 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Disclosure of information under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 - Meeting with Investors/Analysts |
Fri, 10 Mar 2023
Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011. The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011 on March 10 2023 for Docon Technologies Pvt Ltd & API Holdings Ltd |
Fri, 10 Mar 2023
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on March 10 2023 for Docon Technologies Pvt Ltd & API Holdings Ltd |
Tue, 28 Mar 2023 |
|
|
|
|
|